Evidence map›Paper›PMID 32494131›Full record

ArticleInternational journal of nanomedicine2020

Induction of Robust Immune Responses by CpG-ODN-Loaded Hollow Polymeric Nanoparticles for Antiviral and Vaccine Applications in Chickens.

Shu-Yi Lin, Bing-Yu Yao, Che-Ming Jack Hu, Hui-Wen Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Biomolecules · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Nanomedicine based approaches for combating viral infections.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  13. Review
  14. Robust induction of TMolecular therapy. Methods & clinical development · 2021
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shu-Yi LinDepartment of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-4244-7842
Bing-Yu YaoInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Che-Ming Jack HuInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Hui-Wen ChenDepartment of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-0595-3420
Institute of Biomedical Sciences, Academia Sinica · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoultry vaccine has limited choices of adjuvants and is facing severe threat of infectious diseases due to ineffective of widely used commercial vaccines. Thus, development of novel adjuvant that offers safe and effective immunity is of urgent need. MATERIALS AND

methodsThe present research engineers a novel chicken adjuvant with potent immune-potentiating capability by incorporating avian toll-like receptor 21 (TLR21) agonist CpG ODN 2007 with a poly(lactic-co-glycolic acid) (PLGA)-based hollow nanoparticle platform (CpG-NP), which subsequently assessed ex vivo and in vivo.

resultsCpG-NPs with an average diameter of 164 nm capable of sustained release of CpG for up to 96 hours were successfully prepared. With the ex vivo model of chicken bone marrow-derived dendritic cells (chBMDCs), CpG-NP was engulfed effectively and found to induce DC maturation, promoting dendrite formation and upregulation of CD40, CD80 and CCR7. In addition to enhanced expression of IL-1β, IL-6, IL-12 and IFN-γ, 53/84 immune-related genes were found to be stimulated in CpG-NP-treated chBMDCs, whereas only 39 of such genes were stimulated in free CpG-treated cells. These upregulated genes suggest immune skewing toward T helper cell 1 bias and evidence of improved mucosal immunity upon vaccination with the CpG-NP. The CpG-NP-treated chBMDCs showed protective effects to DF-1 cells against avian influenza virus H6N1 infection. Upon subsequent coupling with infectious bronchitis virus subunit antigen administration, chickens were immunostimulated to acquire higher humoral immune response and protective response against viral challenge. CONCLUSTION: This work presents a novel hollow CpG-NP formulation, demonstrating effective and long-lasting immunostimulatory ability ex vivo and in vivo for chickens, as systemically compared to free CpG. This enhanced immune stimulation benefits from high stability and controlled release of internal component of nanoparticles that improve cellular delivery, lymphoid organ targeting and sustainable DC activation. CpG-NP has broad application potential in antiviral and vaccine development.

Indexed as

Adjuvants, ImmunologicAnimalsAntiviral AgentsCell SurvivalChickensDendritic CellsDogsImmunityImmunity, HumoralImmunizationInfectious bronchitis virusMadin Darby Canine Kidney CellsNanoparticlesOligodeoxyribonucleotidesPolylactic Acid-Polyglycolic Acid CopolymerPolymersAdjuvants, ImmunologicAntiviral AgentsCPG-oligonucleotideOligodeoxyribonucleotidesPolylactic Acid-Polyglycolic Acid CopolymerPolymersVaccinesadjuvantantiviral responseCpGinfectious bronchitis virusinfluenza viruspolymeric hollow nanoparticlevaccine

Identifiers

PMID32494131
PMCPMC7227821
OpenAlexW3022197200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.